The FDA NIH Biomarkers, EndpointS, and other Tools (BEST) resource in neuro-oncology

Prognostic value of molecular and imaging biomarkers in patients with supratentorial glioma

(2017) Egesta Lopci et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Bayesian Baskets: A Novel Design for Biomarker-Based Clinical Trials

(2017) Lorenzo Trippa et al.   JOURNAL OF CLINICAL ONCOLOGY

Adult Glioblastoma

(2017) Brian M. Alexander et al.   JOURNAL OF CLINICAL ONCOLOGY

Genome-wide association study of glioma subtypes identifies specific differences in genetic susceptibility to glioblastoma and non-glioblastoma tumors

(2017) Beatrice S Melin et al.   NATURE GENETICS

The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria

(2017) Lakshmi Nayak et al.   NEURO-ONCOLOGY

Leveraging molecular datasets for biomarker-based clinical trial design in glioblastoma

(2017) Shyam K. Tanguturi et al.   NEURO-ONCOLOGY

Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma

(2017) James R. Perry et al.   NEW ENGLAND JOURNAL OF MEDICINE

A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM)

(2017) T. F. Cloughesy et al.   JOURNAL OF CLINICAL ONCOLOGY

The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary

(2016) David N. Louis et al.   ACTA NEUROPATHOLOGICA

Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single and multicenter trials

(2016) Benjamin M. Ellingson et al.   NEURO-ONCOLOGY

The Potential of Radiomic-Based Phenotyping in Precision Medicine

(2016) Hugo J. W. L. Aerts   JAMA Oncology

Biomarker: Predictive or Prognostic?

(2015) Karla V. Ballman   JOURNAL OF CLINICAL ONCOLOGY

Immunotherapy response assessment in neuro-oncology: a report of the RANO working group

(2015) Hideho Okada et al.   LANCET ONCOLOGY

Mutational landscape and clonal architecture in grade II and III gliomas

(2015) Hiromichi Suzuki et al.   NATURE GENETICS

A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma

(2015) Elizabeth R. Gerstner et al.   NEURO-ONCOLOGY

Imaging Genomics of Glioblastoma

(2015) Mohamed G. ElBanan et al.   NEUROIMAGING CLINICS OF NORTH AMERICA

Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors

(2015) Jeanette E. Eckel-Passow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Glutamine-based PET imaging facilitates enhanced metabolic evaluation of gliomas in vivo

(2015) Sriram Venneti et al.   Science Translational Medicine

Detection of Brain Tumor Cells in the Peripheral Blood by a Telomerase Promoter-Based Assay

(2014) Kelly M. MacArthur et al.   CANCER RESEARCH

Benefit From Procarbazine, Lomustine, and Vincristine in Oligodendroglial Tumors Is Associated With Mutation ofIDH

(2014) J. Gregory Cairncross et al.   JOURNAL OF CLINICAL ONCOLOGY

Perfusion Magnetic Resonance Imaging: A Comprehensive Update on Principles and Techniques

(2014) Geon-Ho Jahng et al.   KOREAN JOURNAL OF RADIOLOGY

Progression-free survival: too much risk, not enough reward?

(2014) B. M. Alexander et al.   NEURO-ONCOLOGY

Association between DNA repair gene polymorphisms and risk of glioma: A systematic review and meta-analysis

(2014) Maral Adel Fahmideh et al.   NEURO-ONCOLOGY

A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma

(2014) Mark R. Gilbert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma

(2014) Olivier L. Chinot et al.   NEW ENGLAND JOURNAL OF MEDICINE

A phase I trial of MK-2206 in children with refractory malignancies: A Children's Oncology Group study

(2014) Maryam Fouladi et al.   PEDIATRIC BLOOD & CANCER

Brain Tumor Cells in Circulation Are Enriched for Mesenchymal Gene Expression

(2014) J. P. Sullivan et al.   Cancer Discovery

Net Clinical Benefit Analysis of Radiation Therapy Oncology Group 0525: A Phase III Trial Comparing Conventional Adjuvant Temozolomide With Dose-Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma

(2013) Terri S. Armstrong et al.   JOURNAL OF CLINICAL ONCOLOGY

Interactions of miR-323/miR-326/miR-329 and miR-130a/miR-155/miR-210 as prognostic indicators for clinical outcome of glioblastoma patients

(2013) Shuwei Qiu et al.   Journal of Translational Medicine

Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials

(2013) K. Han et al.   NEURO-ONCOLOGY

Loss of heterozygosity 1p/19q and survival in glioma: a meta-analysis

(2013) Jiaxin Zhao et al.   NEURO-ONCOLOGY

Differentiating tumor recurrence from treatment necrosis: a review of neuro-oncologic imaging strategies

(2013) Nishant Verma et al.   NEURO-ONCOLOGY

miR-21 in the Extracellular Vesicles (EVs) of Cerebrospinal Fluid (CSF): A Platform for Glioblastoma Biomarker Development

(2013) Johnny C. Akers et al.   PLoS One

Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402

(2012) Gregory Cairncross et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951

(2012) Martin J. van den Bent et al.   JOURNAL OF CLINICAL ONCOLOGY

Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial

(2012) Annika Malmström et al.   LANCET ONCOLOGY

A low-frequency variant at 8q24.21 is strongly associated with risk of oligodendroglial tumors and astrocytomas with IDH1 or IDH2 mutation

(2012) Robert B Jenkins et al.   NATURE GENETICS

Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy

(2012) Huilin Shao et al.   NATURE MEDICINE

Pseudoprogression and Pseudoresponse: Imaging Challenges in the Assessment of Posttreatment Glioma

(2011) L.C. Hygino da Cruz et al.   AMERICAN JOURNAL OF NEURORADIOLOGY

Role of isocitrate dehydrogenase in glioma

(2011) Brian M Alexander et al.   Expert Review of Neurotherapeutics

Prognostic and predictive value of epigenetic silencing of MGMT in patients with high grade gliomas: a systematic review and meta-analysis

(2011) Robert A. Olson et al.   JOURNAL OF NEURO-ONCOLOGY

Prediagnostic Plasma IgE Levels and Risk of Adult Glioma in Four Prospective Cohort Studies

(2011) F. C. F. Calboli et al.   JNCI-Journal of the National Cancer Institute

A multigene predictor of outcome in glioblastoma

(2011) H. Colman et al.   NEURO-ONCOLOGY

Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma

(2011) R. J. Young et al.   NEUROLOGY

Molecular diagnostics of gliomas: state of the art

(2010) Markus J. Riemenschneider et al.   ACTA NEUROPATHOLOGICA

Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

(2010) Patrick Y. Wen et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers

(2010) Michael Jansen et al.   LANCET NEUROLOGY

Mutant IDH1-specific immunohistochemistry distinguishes diffuse astrocytoma from astrocytosis

(2009) Sandra Camelo-Piragua et al.   ACTA NEUROPATHOLOGICA

Characterization of R132H Mutation-specific IDH1 Antibody Binding in Brain Tumors

(2009) David Capper et al.   BRAIN PATHOLOGY

IDH1 Mutations as Molecular Signature and Predictive Factor of Secondary Glioblastomas

(2009) S. Nobusawa et al.   CLINICAL CANCER RESEARCH

MGMTPromoter Methylation Is Prognostic but Not Predictive for Outcome to Adjuvant PCV Chemotherapy in Anaplastic Oligodendroglial Tumors: A Report From EORTC Brain Tumor Group Study 26951

(2009) Martin J. van den Bent et al.   JOURNAL OF CLINICAL ONCOLOGY

Isocitrate Dehydrogenase 1 Codon 132 Mutation Is an Important Prognostic Biomarker in Gliomas

(2009) Marc Sanson et al.   JOURNAL OF CLINICAL ONCOLOGY

NOA-04 Randomized Phase III Trial of Sequential Radiochemotherapy of Anaplastic Glioma With Procarbazine, Lomustine, and Vincristine or Temozolomide

(2009) Wolfgang Wick et al.   JOURNAL OF CLINICAL ONCOLOGY

Assessment of physical functioning in recurrent glioma: preliminary comparison of performance status to functional capacity testing

(2009) Lee W. Jones et al.   JOURNAL OF NEURO-ONCOLOGY

Detecting an Overall Survival Benefit that Is Derived From Progression-Free Survival

(2009) Kristine R. Broglio et al.   JNCI-Journal of the National Cancer Institute

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

(2009) Roger Stupp et al.   LANCET ONCOLOGY

Fundamentals of Quantitative Dynamic Contrast-Enhanced MR Imaging

(2009) Michael J. Paldino et al.   Magnetic Resonance Imaging Clinics of North America

MGMT promoter methylation in malignant gliomas: ready for personalized medicine?

(2009) Michael Weller et al.   Nature Reviews Neurology

Risk analysis of severe myelotoxicity with temozolomide: The effects of clinical and genetic factors

(2009) Terri S. Armstrong et al.   NEURO-ONCOLOGY

IDH1andIDH2Mutations in Gliomas

(2009) Hai Yan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oligodendrogliomas: Molecular Biology and Treatment

(2009) J. E. C. Bromberg et al.   ONCOLOGIST

Validation of Analytic Methods for Biomarkers Used in Drug Development

(2008) C. H. Chau et al.   CLINICAL CANCER RESEARCH

Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas

(2008) Kathleen R. Lamborn et al.   NEURO-ONCOLOGY